Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemegride
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Bemegride is a central nervous system (CNS) stimulant and respiratory stimulant that was first synthesized in 1911. It has been primarily used as an antidote for barbiturate poisoning and to induce convulsions in experimental animals. Its mechanism of action involves antagonism of the GABAA receptor, suppressing both GABA-induced and pentobarbitone-induced currents, thereby counteracting CNS depression caused by barbiturates. Historically marketed under several brand names including Megimide and Eukraton, bemegride is classified chemically as a piperidinedione derivative[1][2][3][4][5][6][8].
- Brand names
- MegimideEukratonMalysolMegibalMegimid
- Other names
- BemegridaBemegridum3-Ethyl-3-methylglutarimide4-Ethyl-4-methylpiperidine-2,6-dioneMethetharimideMikedimideZentraleptinAgipnonAhypnonAntibarbiBemegridBemigrideBenegrid3-Methyl–3–ethylglutarimide2,6-Piperidinedione, 4–ethyl–4–methyl–
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on bemegride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemegride.